Roles of miR-4442 in Colorectal Cancer: Predicting Early Recurrence and Regulating Epithelial-Mesenchymal Transition

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Early recurrence in colorectal cancer (CRC) significantly worsens patient prognosis.
• Identifying reliable biomarkers for early CRC recurrence is crucial for timely intervention.
• Circulating microRNAs are emerging as promising biomarkers in various cancers.

Purpose of the Study:

• To identify circulating microRNAs as biomarkers for early CRC recurrence.
• To elucidate the functional role of identified microRNAs in CRC progression.
• To investigate the association of miR-4442 with clinicopathological features and survival.

Main Methods:

• MicroRNA array analysis of preoperative and postoperative plasma from CRC patients.
• Association analysis of plasma miR-4442 levels with clinicopathological features and recurrence-free survival in 108 patients.
• In vitro cell-function analyses to assess the role of miR-4442 in CRC cell proliferation, migration, and invasion.
• Examination of miR-4442's involvement in epithelial-mesenchymal transition (EMT) and its target genes.

Main Results:

• Preoperative plasma miR-4442 levels were significantly associated with CRC recurrence, increasing with earlier recurrence.
• miR-4442 demonstrated high sensitivity and specificity as a biomarker for early CRC recurrence.
• Overexpression of miR-4442 in CRC cells promoted proliferation, migration, and invasion, decreasing E-cadherin and RBMS1 while increasing N-cadherin and Snail1.
• miR-4442 was found to directly target the mRNA of RBMS1, regulating EMT in CRC.

Conclusions:

• Plasma miR-4442 is a clinically valuable biomarker for predicting early recurrence in colorectal cancer patients.
• miR-4442 plays a significant role in regulating epithelial-mesenchymal transition (EMT) in CRC by targeting RBMS1.
• These findings highlight miR-4442 as a potential therapeutic target for preventing CRC recurrence and metastasis.